References
- Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005; 33:676–82.
- Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lasseter KC, Kraft WK, Greenberg H, Waldman SA. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004;48:4306–14.
- Cancidas: Package Insert and Label information. Merck Sharp & Dohme Corp., last revised 8 January 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021227s031lbl-pdf. (Accessed on the 25 May 2013)
- Belmares J, Colaizzi L, Parada JP, Johnson S. Caspofungin treatment failure in a patient with invasive candidiasis and concomitant rifampicin treatment. Int J Antimicrob Agents 2005;26:264–5.
- Stone JA, Xu X, Winchell GA, Deutsch PJ, Pearson PG, Migoya EM, Mistry GC, Xi L, Miller A, Sandhu P, Singh R, deLuna F, Dilzer SC, Lasseter KC. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48:815–23.